CelLBxHealth plc
0.63
GBX
-0.05
(-7.41%)
ISIN
GB0034330679
Return %
Stock
S&P 500
1Y
-75.96
14.20
3Y
-94.56
81.12
5Y
-99.50
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Peter Michael Collins
- Full Time Employees
- 44
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Surrey Research Park Guildford SU United Kingdom GU2 7AF
- IPO Date
- Mar 17, 2004
- Website
- cellbxhealth.com
- Similar Companies
- Business
- CelLBxHealth plc engages in the development and commercialization of cancer diagnostics technology, focusing on the Parsortix cell separation system for liquid biopsy applications. The company supplies the Parsortix platform, associated consumables and assays, and provides laboratory services, including clinical-trial support and bespoke assay development, through its GCLP-compliant UK laboratory. CelLBxHealth operates primarily in Europe and North America, with revenue concentration in Europe, and targets pharmaceutical, biotechnology, contract research organization (CRO), and clinical laboratory customers for adoption of its Parsortix system and related products. Main products and services - Parsortix platform: medical device system for separation and harvest of circulating tumor cells (CTCs) from peripheral blood; includes platform hardware, proprietary microfluidic cartridge consumables, and related assay kits. - Parsortix consumables and assays: disposable cartridges, reagents, and companion assays enabling CTC capture, enrichment, and downstream analyses. - Laboratory services: GCLP-compliant clinical‑trial support, assay development, and validation services delivered from CelLBxHealth’s UK laboratory; fast-track project design and execution for diagnostic product development. - Research and development collaborations: co-development programs with CROs and diagnostic partners to optimize Parsortix workflows and expand assay portfolios. - Data and analytics services (where applicable): aggregation and interpretation support for CTC-based diagnostics within collaborative studies and clinical trials. Latest major company changes - Strategic shift toward commercialization: the company progresses from a research-centric posture to a commercially oriented model, pursuing international diagnostic collaborations to scale Parsortix adoption and drive consumable sales; funding rounds are utilized to support restructuring, global partnerships, and broader market deployment. - Fundraising and capital structure actions: a recent equity raise to fund strategic realignment, product commercialization, and expansion initiatives, coupled with management-led restructuring to reduce costs and accelerate go-to-market plans. - Product and service expansions: launch and scaling of new CTC assay offerings and downstream analytical capabilities aligned with the Parsortix platform; expansion of clinical laboratory services and bespoke assay development to support partnerships and regulatory pathways. - Partnerships and collaborations: increased alliances with international diagnostic firms and CROs to accelerate Parsortix adoption, enable broader access to markets, and integrate Parsortix-based workflows into standard clinical practice. - Operational refinements: optimization of manufacturing and supply chain for Parsortix consumables, governance enhancements, and organization-wide cost-saving measures implemented to improve profitability and focus on core commercial activities. Additional context - Industry and segments: medical diagnostics; liquid biopsy; cancer diagnostics; in vitro diagnostics (IVD) equipment and services. - Target markets: pharmaceutical and biotech developers, CROs, clinical laboratories, and hospital-based diagnostics programs seeking non-invasive cancer detection and monitoring solutions. - Geographic operations: Europe and North America as primary regions, with ongoing efforts to expand into additional international markets. - Corporate structure: public company listed on the London Stock Exchange AIM market; operates as a stand-alone entity with potential interactions with parent or affiliated research platforms through strategic partnerships. - Founding and headquarters: founded in the early 2010s; headquarters located in the United Kingdom (office and R&D facilities in the UK and supporting operations in Europe). - Subsidiaries and affiliations: maintains core technology rights to Parsortix platform, with collaboration agreements and service entities supporting commercial activities and lab services.